title: Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification.
abstract: BACKGROUND
  A considerable number of patients with metastatic colorectal cancer progress after exhausting all approved standard therapies but maintain an adequate performance status and could be candidates for further treatment. We aim at reviewing our experience with sorafenib treatment of a patient with FLT3 mutation in refractory metastatic colorectal cancer.
  
  
  METHODS
  Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated.
  
  
  RESULTS
  The patient with metastatic colorectal cancer, aged 51 years, showed significant symptomatic and laboratory improvement with sorafenib treatment (400 mg twice daily).
  
  
  CONCLUSIONS
  The presented case illustrates how an aggressive and refractory colorectal tumor may respond well to targeted therapy.
authors.affiliation: Centro Oncológico Antônio Ermírio de Moraes, São Paulo, Brazil.
authors.forename: Raphael Brandão
authors.initials: RB
authors.lastname: Moreira
authors.affiliation: Centro Oncológico Antônio Ermírio de Moraes, São Paulo, Brazil.
authors.forename: Renata D'Alpino
authors.initials: RD
authors.lastname: Peixoto
authors.affiliation: Centro Oncológico Antônio Ermírio de Moraes, São Paulo, Brazil.
authors.forename: Marcelo Rocha
authors.initials: MR
authors.lastname: de Sousa Cruz
keywords: FLT3 amplification; Metastatic colorectal cancer; Sorafenib
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: Invest New Drugs. 2013 Apr;31(2):345-54
references.pmid: 22615057
references.citation: Leukemia. 2006 Nov;20(11):2008-14
references.pmid: 16990784
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Mol Cancer. 2010 Nov 10;9:292
references.pmid: 21067588
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2505-12
references.pmid: 16636341
references.citation: BMC Cancer. 2011 Sep 30;11:419
references.pmid: 21961577
references.citation: Nature. 2012 Jul 18;487(7407):330-7
references.pmid: 22810696
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7271-8
references.pmid: 17189398
references.citation: Leukemia. 2001 Jul;15(7):1001-10
references.pmid: 11455967
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Gastroenterology. 1998 Nov;115(5):1090-5
references.pmid: 9797363
references.citation: J Leukoc Biol. 1999 Mar;65(3):372-80
references.pmid: 10080542
references.citation: Science. 2007 Nov 16;318(5853):1108-13
references.pmid: 17932254
references.citation: Ann Surg Oncol. 2009 Dec;16(12):3279-88
references.pmid: 19688403
references.citation: Science. 2006 Oct 13;314(5797):268-74
references.pmid: 16959974
references.citation: N Engl J Med. 2001 Apr 5;344(14):1031-7
references.pmid: 11287972
references.citation: Cancer Res. 2009 Apr 1;69(7):3032-41
references.pmid: 19318574
references.citation: Nat Rev Cancer. 2009 Oct;9(10 ):749-58
references.pmid: 19776744
references.citation: Annu Rev Pathol. 2011;6:479-507
references.pmid: 21090969
references.citation: Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):213-20
references.pmid: 20708486
references.citation: Mol Cancer Ther. 2008 Oct;7(10 ):3129-40
references.pmid: 18852116
references.citation: Indian J Cancer. 2011 Jan-Mar;48(1):47-54
references.pmid: 21248446
references.citation: Cancer Res. 1989 Sep 1;49(17):4682-9
references.pmid: 2547513
references.citation: Nat Genet. 2011 Sep 04;43(10):964-8
references.pmid: 21892161
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Gastroenterology. 2008 Feb;134(2):379
references.pmid: 18242200
references.citation: Nat Biotechnol. 2013 Nov;31(11):1023-31
references.pmid: 24142049
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Oncologist. 2008 Aug;13(8):845-58
references.pmid: 18695262
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Oncol Rep. 2012 May;27(5):1303-11
references.pmid: 22323095
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Cancer Discov. 2012 Jan;2(1):82-93
references.pmid: 22585170
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: Blood. 2000 Dec 1;96(12):3907-14
references.pmid: 11090077